SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Human Genome Sciences, Inc. (HGSI) -- Ignore unavailable to you. Want to Upgrade?


To: Elmer who wrote (333)9/1/1999 1:17:00 PM
From: Xpiderman  Read Replies (1) | Respond to of 1127
 
Credit Suisse First Boston said Wednesday that analyst Alex To raised his price targets on three biotechnology companies, citing positive product developments and profit outlooks for the firms.

-- Said raised Human Genome Sciences (Nasdaq:HGSI - news) price target to $90 from $70

-- Cited expanding value of company's patents covering gene's linked to diseases and product developments that are ''progressing well.''


Shares of Human Genome Sciences climbed 3 to 71-1/16.